Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Biochem Funct ; 41(8): 1060-1075, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37916887

ABSTRACT

Cardiovascular diseases (CVDs) identified as a serious public health problem. Although there is a lot of evidence that inflammatory processes play a significant role in the progression of CVDs, however, the precise mechanism is not fully understood. Nevertheless, recent studies have focused on inflammation and its related agents. Nucleotide oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) is a type of pattern recognition receptor (PRR) that can recognize pathogen-associated molecular patterns and trigger innate immune response. NLRP3 is a component of the NOD-like receptor (NLR) family and have a pivotal role in detecting damage to cardiovascular tissue. It is suggested that activation of NLRP3 inflammasome leads to initiating and propagating the inflammatory response in cardiomyopathy. So, late investigations have highlighted the NLRP3 inflammasome activation in various forms of cardiomyopathy. On the other side, it was shown that noncoding RNAs (ncRNAs), particularly, microRNAs, lncRNAs, and circRNAs possess a regulatory function in the immune system's inflammatory response, implicating their involvement in various inflammatory disorders. In addition, their role in different cardiomyopathies was indicated in recent studies. This review article provides a summary of recent advancements focusing on the function of the NLRP3 inflammasome in common CVDs, especially cardiomyopathy, while also discussing the therapeutic potential of inhibiting the NLRP3 inflammasome regulated by ncRNAs.


Subject(s)
Cardiomyopathies , NLR Family, Pyrin Domain-Containing 3 Protein , Humans , Cardiomyopathies/genetics , Cardiomyopathies/metabolism , Inflammasomes/metabolism , Inflammation , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
2.
Galen Med J ; 12: 1-9, 2023.
Article in English | MEDLINE | ID: mdl-38774845

ABSTRACT

Delirium and dementia are considered to be the most significant postoperative neurocognitive complications in patients undergoing cardiac surgery, particularly those aged 60 years and older, which reduces the post-surgery quality of life, prolongs hospitalization, increases costs, and elevated the rates of mortality. Nevertheless, the etiology, risk factors, and predictive biomarkers, have not been well elucidated particularly, in patients with unmanifested underline cognitive impairments. The present study aimed to review the findings on the etiology, factors increasing the risk of incidence, and predictive biomarkers of postoperative delirium and dementia after cardiac surgery, and to describe the suggested pharmacological and non-pharmacological interventions.

3.
Vasc Health Risk Manag ; 16: 99-101, 2020.
Article in English | MEDLINE | ID: mdl-32280232

ABSTRACT

Hemitruncus arteriosus refers to an uncommon congenital cardiovascular abnormality. It usually presents in infancy and leads to the development of pulmonary hypertension, heart failure, and in severe cases maybe death. Herein, we reported hemitruncus arteriosus in a 10-day-old neonate with respiratory distress, patent ductus arteriosus, and thrombocytopenia.


Subject(s)
Ductus Arteriosus, Patent/complications , Thrombocytopenia/complications , Truncus Arteriosus, Persistent/complications , Disease Progression , Ductus Arteriosus, Patent/diagnostic imaging , Ductus Arteriosus, Patent/physiopathology , Ductus Arteriosus, Patent/therapy , Fatal Outcome , Humans , Infant, Newborn , Male , Respiratory Distress Syndrome, Newborn/etiology , Thrombocytopenia/diagnosis , Thrombocytopenia/therapy , Truncus Arteriosus, Persistent/diagnostic imaging , Truncus Arteriosus, Persistent/physiopathology , Truncus Arteriosus, Persistent/therapy
4.
Pediatr Cardiol ; 37(1): 55-61, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26215768

ABSTRACT

Better postoperative management of patients who have undergone single ventricle (SV) Fontan procedure could potentially reduce long-term complications and improve the quality of life for patients. The present study determined the effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Patients who had undergone SV modified Fontan operation were enrolled in this clinical trial. The demographic characteristics of the patients were recorded. Before administration of tadalafil and after the trial, ventricular function (MPI, EF, FS, E/A, VTI), exercise performance, and endothelial function were evaluated for sonographic and biochemical markers (FMD, IMT, ICAM, VCAM, NO) using echocardiography, exercise testing, vascular ultrasonography, and biochemical measurements, respectively. A single dose of tadalafil of 1 mg/kg was administered daily for 6 weeks, and the functional class of the patients before and after tadalafil was determined. A total of 15 patients completed this clinical trial. Tadalafil was shown to have a significant effect on myocardial function, exercise performance, and improvement in NYHA functional class (p < 0.05) of study population. It had no significant effect on the biochemical variables and endothelial function except for IMT (p > 0.05), which decreased significantly after tadalafil administration (p < 0.05). The findings indicate that tadalafil is a safe, well-tolerated agent for the use after modified Fontan operation to improve myocardial function and exercise performance and possibly reduce long-term morbidity and mortality of patients. More conclusive results could be obtained from further study with a larger sample size and long-term follow-up.


Subject(s)
Endothelium/drug effects , Exercise/physiology , Fontan Procedure , Heart Ventricles/drug effects , Phosphodiesterase 5 Inhibitors/therapeutic use , Tadalafil/therapeutic use , Adolescent , Adult , Child , Echocardiography , Exercise Test , Female , Heart Ventricles/physiopathology , Humans , Male , Myocardium , Phosphodiesterase 5 Inhibitors/adverse effects , Postoperative Period , Tadalafil/adverse effects , Young Adult
5.
ARYA Atheroscler ; 10(3): 175-8, 2014 May.
Article in English | MEDLINE | ID: mdl-25161690

ABSTRACT

BACKGROUND: Tachycardia-induced cardiomyopathy (TIC) is a rare cause of dilated cardiomyopathy (DCMP). The diagnosis can be missed because tachycardia is a common symptom in DCMP. CASE REPORT: We reviewed a case 5-year-old with palpitation and dyspnea with symptoms and signs of heart failure that diagnosed as DCMP initially. Then, in the evaluation for cause of tachycardia, atrial tachycardia was detected. Hence, treatment with flecainide was started and after 3 months, left ventricular (LV) systolic function and symptoms of the patient was relieved. CONCLUSION: TIC should be suspected in all patients with unexplained LV dysfunctions in the setting of a persistent tachyarrhythmia.

SELECTION OF CITATIONS
SEARCH DETAIL
...